Literature DB >> 18379928

Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release.

P S Hiremath1, R N Saha.   

Abstract

Hydrophilic controlled release matrix tablets of rifampicin, a poorly soluble drug, have been formulated using hydroxypropyl methylcellulose (HPMC) polymer (low, medium, and high viscosity) by direct compression method. Influence of formulation variables and process parameters such as drug:HPMC ratio, viscosity grade of HPMC, drug particle size, and compression force on the formulation characters and drug release has been studied. Our results indicated that the release rate of the drug and the mechanism of release from the HPMC matrices are mainly controlled by the drug:HPMC ratio and viscosity grade of the HPMC. In general, decrease in the drug particle size decreased the drug release. Lower viscosity HPMC polymer was found to be more sensitive to the effect of compression force than the higher viscosity. The formulations were found to be stable and reproducible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379928     DOI: 10.1080/10717540801952498

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  3 in total

1.  Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies.

Authors:  Praveen S Hiremath; Ranendra N Saha
Journal:  AAPS PharmSciTech       Date:  2008-11-19       Impact factor: 3.246

2.  Synthesis and characterization of antibacterial drug loaded β-tricalcium phosphate powders for bone engineering applications.

Authors:  Aysenur Topsakal; Nazmi Ekren; Osman Kilic; Faik N Oktar; Mahir Mahirogullari; Ozan Ozkan; Hilal Turkoglu Sasmazel; Mustafa Turk; Iuliana M Bogdan; George E Stan; Oguzhan Gunduz
Journal:  J Mater Sci Mater Med       Date:  2020-01-21       Impact factor: 3.896

3.  Development of in vitro - in vivo correlations for newly optimized Nimesulide formulations.

Authors:  Muhammad Hanif; Muhammad Harris Shoaib; Rabia Ismail Yousuf; Farya Zafar
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.